Andrea Tripoli

Dr. Andrea Tripoli

IRCCS San Raffaele Institute, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RHRene Hameau
Rene Hameau
MAMarco B. Ancona
Marco B. Ancona
RVRomano Vittorio
Romano Vittorio
LFLuca Angelo Ferri
Luca Angelo Ferri
BBBarbara Bellini
Barbara Bellini
MMMatteo Montorfano
Matteo Montorfano
Underexpansion of a self-expanding transcatheter aortic valve (TAVI) is a critical issue that can negatively impact long-term outcomes, including paravalvular leak, valve thrombosis, and increased mortality. This paper provides a comprehensive review of the pathophysiology and consequences of such complications, including three primary mechanisms: (1) infolding, (2) incorrect site of crossing and (3) true underexpansion. It also discusses strategies to address these challenges, including pre-procedural planning and procedural techniques to ensure proper valve deployment and expansion. Mitigating these issues is essential to improving both immediate and long-term outcomes in TAVI patients.

26 October 2025 in Heart & Lung
Verified
Journal Article
Open access
MSMiguel A. Samaniego-Laguna
Miguel A. Samaniego-Laguna
ATAndrea Tripoli
Andrea Tripoli
NVNorma Nicole Gamarra Valverde
Norma Nicole Gamarra Valverde
SSShivraj Selvam
Shivraj Selvam
Alejandro N BarbagelataAlejandro N Barbagelata
Alejandro N Barbagelata
JGJuliana Giorgi
Juliana Giorgi
Cardiac myosin activators (CMAs) have been explored as a potential therapy to enhance cardiac contractility in patients with heart failure with reduced ejection fraction (HFrEF). However, their effect on clinical outcomes, including mortality, cardiovascular (CV) events, and heart failure (HF) symptoms, remains unclear. This study aimed to evaluate the efficacy and safety of CMAs compared to placebo in patients with HFrEF through a systematic review and meta-analysis of randomized controlled trials. A systematic search of PubMed, Cochrane, Embase, and Scopus identified randomized controlled trials comparing CMAs to placebo in HFrEF patients. Meta-analyses were performed using a random-effects model, including 10,019 patients from nine trials, with 5204 receiving CMAs. CMAs had no significant effect on CV death (risk ratio [RR]: 1.01; 95 % confidence interval [CI]: 0.92-1.10; p = 0.85), HF events (RR: 0.95; 95 % CI: 0.89-1.02; p = 0.15), or all-cause mortality (RR: 1.00; 95 % CI: 0.93-1.07; p = 0.95). However, CMAs significantly reduced the composite outcome of CV death, HF hospitalization, and urgent outpatient visits for HF (hazard ratio [HR]: 0.92; 95 % CI: 0.90-0.93; p < 0.00001) and lowered stroke risk compared to placebo (p = 0.006). CMAs, particularly omecamtiv mecarbil, did not significantly impact all-cause mortality, cardiovascular death, or HF recurrence in patients with HFrEF. However, modest reductions were observed in composite outcomes and stroke. These findings should be interpreted cautiously, and further trials are needed to validate their clinical role.